创伤后全身性纤溶亢进:患者血浆叠加机制靶向蛋白质组学分析的初步研究
该初步研究用靶向蛋白质组学分析创伤后纤溶亢进(HF)患者血浆蛋白。HF定义为tPA刺激下血栓弹力图(TEG)Ly30>50%。采集10例HF、10例纤溶正常(EF)创伤患者及10例健康对照的血样,在野外或急诊到达时留取,用TEG表征血块形成。HF患者显示纤溶酶原激活增加;33种蛋白较健康对照和EF患者显著降低(p<0.005),其中17种为凝血蛋白伴抗蛋白酶消耗,另16种提示旁路补体途径激活、载体蛋白耗竭及4种糖蛋白。CXC7在所有创伤患者中较健康对照升高(p<0.005)。HF患者凝血因子II、X、XIII意外降低而血块形成参数(SP、R时间、角度)无变化。
要点
- HF定义为tPA刺激下TEG Ly30>50%,此类患者纤溶酶原激活增加且早期死亡率增高。
- HF患者33种蛋白较健康对照和EF患者显著降低(p<0.005),17种为凝血蛋白伴抗蛋白酶消耗。
- HF患者凝血因子II、X、XIII意外降低,但血块形成参数(SP、R时间、角度)无变化。
- CXC7在所有创伤患者中较健康对照升高(p<0.005),35种蛋白在三组间无变化(p>0.1,倍数变化0.75-1.3)。
- HF患者血块稳定性降低,经tPA刺激TEG证实。
适用人群与场景
- 严重创伤患者,血样在野外或急诊到达时采集。
- HF组:tPA刺激下TEG Ly30>50%的创伤患者;EF组:Ly30正常的创伤患者;对照组:健康人。
诊断标准与关键阈值
- HF定义:tPA刺激下血栓弹力图(TEG)Ly30>50%。
- EF定义:30分钟纤溶时间(Ly30)正常的创伤患者。
研究设计与关键结果
- 研究类型:初步研究,靶向蛋白质组学分析;样本量:HF组10例、EF组10例、健康对照10例。
- HF患者显示纤溶酶原激活增加。
- HF患者33种蛋白较健康对照和EF患者显著降低(p<0.005),其中17种为凝血蛋白伴抗蛋白酶消耗。
- 另16种降低蛋白提示旁路补体途径激活、载体蛋白耗竭及4种糖蛋白。
- CXC7在所有创伤患者中较健康对照升高(p<0.005);35种蛋白在三组间无变化(p>0.1,倍数变化0.75-1.3)。
- HF患者凝血因子II、X、XIII降低,但血块形成参数(SP、R时间、角度)无变化;tPA刺激TEG证实血块稳定性降低。
证据类型、等级与局限
- 证据类型:初步研究(靶向蛋白质组学分析);证据等级:预后性,III级。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为HF患者特定蛋白显著降低支持创伤诱导纤溶亢进的已知机制,并意外发现凝血因子II、X、XIII降低而血块形成无变化。
- 作者认为HF患者血块稳定性降低经tPA刺激TEG证实。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Viscoelastic measurements of hemostasis indicate that 20% of seriously injured patients exhibit systemic hyperfibrinolysis, with increased early mortality. These patients have normal clot formation with rapid clot lysis. Targeted proteomics was applied to quantify plasma proteins from hyperfibrinolytic (HF) patients to elucidate potential pathophysiology.
METHODS: Blood samples were collected in the field or at emergency department arrival and thrombelastography (TEG) was used to characterize in vitro clot formation under native and tissue plasminogen activator (tPA)-stimulated conditions. Ten samples were taken from injured patients exhibiting normal lysis time at 30 min (Ly30), "eufibrinolytic" (EF), 10 from HF patients, defined as tPA-stimulated TEG Ly30 >50%, and 10 from healthy controls. Trauma patient samples were analyzed by targeted proteomics and ELISA assays for specific coagulation proteins.
RESULTS: HF patients exhibited increased plasminogen activation. Thirty-three proteins from the HF patients were significantly decreased compared with healthy controls and EF patients; 17 were coagulation proteins with anti-protease consumption (p < 0.005). The other 16 decreased proteins indicate activation of the alternate complement pathway, depletion of carrier proteins, and four glycoproteins. CXC7 was elevated in all injured patients versus healthy controls (p < 0.005), and 35 proteins were unchanged across all groups (p > 0.1 and fold change of concentrations of 0.75-1.3).
CONCLUSION: HF patients had significant decreases in specific proteins and support mechanisms known in trauma-induced hyperfibrinolysis and also unexpected decreases in coagulation factors, factors II, X, and XIII, without changes in clot formation (SP, R times, or angle). Decreased clot stability in HF patients was corroborated with tPA-stimulated TEGs.
LEVEL OF EVIDENCE: Prognostic, level III.
参考来源
- Banerjee A, Silliman CC, Moore EE, et al. Systemic hyperfibrinolysis after trauma: a pilot study of targeted proteomic analysis of superposed mechanisms in patient plasma. J Trauma Acute Care Surg. 2018. PMID: 29554044. doi:10.1097/TA.0000000000001878
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。